详情页 - 广东省中医院知识库

当前位置：首页 > 详情页

Cell Differentiation Agent-2 (CDA-2) Inhibits the Growth and Migration of Saos-2 Cells via miR-124/MAPK1.

12| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Orthopedics, The Third Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, People’s Republic of China [2]Department of Pathology, Guangdong Women and Children Hospital, Guangzhou, Guangdong, People’s Republic of China [3]Department of Oncology, Affiliated Tumor Hospital of Guangzhou University, Guangzhou, Guangdong, People’s Republic of China [4]Department of Oncology, Hospital of Ruikang Affiliated to Guangxi University of Chinese Medicine, Guangxi, People’s Republic of China

出处：

DOI：

ISSN：

关键词： cell differentiation agent 2 osteosarcoma miR-124 MAPK1

摘要：

CDA-2 (cell differentiation agent 2), isolated from healthy human urine, exerts antitumor effects in multiple types of cancer cells. However, its role in osteosarcoma has not been studied. The MTT assay was used to examine the cell proliferation rate. A colony formation assay was used to examine cell growth. The Transwell assay was used to examine cell migration ability. A real-time PCR assay was used to examine the expression levels of miR-124 and MAPK1. A Western blot assay was used to examine protein expression levels. MAPK1 was selected as a possible target of miR-124, and the targeting relationship was examined by a luciferase reporter assay. We revealed that CDA-2 decreased the growth, migration and invasion ability of the osteosarcoma cell line Saos-2. Further study revealed that CDA-2 elevated the expression level of miR-124. MAPK1 was identified as a downstream target of miR-124. Knockdown of miR-124 or overexpression of MAPK1 counteracted CDA-2's effects on cell growth and invasion. Our data revealed that the miR-124/MAPK1 axis mediated CDA-2's function in Saos-2 cells. CDA-2 can be used as a new treatment strategy for osteosarcoma. © 2020 Li et al.

语种：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2019]版：

大类 | 3 区医学

小类 | 3 区肿瘤学

最新[2025]版：

大类 | 4 区医学

小类 | 4 区肿瘤学

JCR分区：

出版当年[2018]版：

Q3 ONCOLOGY

最新[2023]版：

Q3 ONCOLOGY

影响因子： 2.5 最新[2023版] 2.8 最新五年平均 2.243 出版当年[2018版] 0 出版当年五年平均 3.702 出版前一年[2017版] 2.886 出版后一年[2019版]

第一作者：

第一作者机构： [1]Department of Orthopedics, The Third Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, People’s Republic of China

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]miR-124 and miR-9 mediated downregulation of HDAC5 promotes neurite development through activating MEF2C-GPM6A pathway. [2]MiR-124-3p mediates gastric cancer cell ferroptosis induced by an anti-cancer drug polyphyllin I [3]miR-124-3p promotes BMSC osteogenesis via suppressing the GSK-3β/β-catenin signaling pathway in diabetic osteoporosis rats. [4]Dynamic changes of behaviors, dentate gyrus neurogenesis and hippocampal miR-124 expression in rats with depression induced by chronic unpredictable mild stress. [5]Advances in limb salvage treatment of osteosarcoma. [6]CBX2 Inhibits Neurite Development by Regulating Neuron-Specific Genes Expression. [7]Targeted Delivery of Chemotherapeutic Agents for Osteosarcoma Treatment. [8]Abnormal DNA methylation may contribute to the progression of osteosarcoma. [9]Non-coding RNAs as potential biomarkers in osteosarcoma [10]Integral Analyses of Competing Endogenous RNA Mechanisms and DNA Methylation Reveal Regulatory Mechanisms in Osteosarcoma.